Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H. P. Hartung, R. Hohlfeld, U. Baumhackl, T. Berger, F. Deisenhammer, F. Fazekas, M. Freimüller, H. Kollegger, W. Kristoferitsch, H. Lassmann, H. Markut, S. Strasser-Fuchs, K. Vass, C. Sindic, M. B. D'hooghe, S. PodobnikE. Havrdova, I. Elovaara, M. Clanet, C. Confavreux, G. Edan, C. Lubetzki, H. Altenkirch, S. Bamborschke, K. Baum, A. Bayas, R. Benecke, W. Brück, M. Buttmann, A. Chan, M. Daumer, D. Dommasch, W. G. Elias, E. Fasshauer, P. Flachenecker, J. Haas, G. Haferkamp, P. Haller, C. Heesen, M. Heibel, F. Heidenreich, B. Hemmer, T. Henze, R. W.C. Janzen, G. Japp, S. Jung, E. Jügelt, B. Kallmann, B. C. Kieseier, C. Kleinschnitz, J. Köhler, W. Köhler, W. Kölmel, N. König, G. Lehrieder, V. Leussink, K. Lowitzsch, M. Mäurer, U. Manegold, A. Melms, J. Mertin, S. G. Meuth, O. Neuhaus, P. Oschmann, H. F. Petereit, M. Pette, D. Pöhlau, D. Pohl, K. Ruprecht, M. Sailer, H. Schipper, S. Schmidt, G. Schock, M. Schulz, S. Schwarz, G. Schwendemann, D. Seidel, N. Sommer, M. Stangel, E. Stark, A. Steinbrecher, G. Stoll, H. Tumani, R. Voltz, F. Weber, F. Weilbach, H. Wiethölter, B. Wildemann, U. K. Zettl, T. Ziemssen, F. Zipp, R. Zschenderlein, A. Orologas, A. Guseo, S. Bergmann, M. Pugliatti, K. M. Myhr, G. Izquierdo, C. Bassetti, K. Beer, S. Beer, U. Buettner, M. Chofflon, A. Gass, N. Goebels, M. Götschi-Fuchs, L. Kappos, J. Kesselring, H. P. Ludin, H. Mattle, M. Schluep, C. Vaney, D. Bates

Research output: Contribution to journalReview articlepeer-review

204 Scopus citations

Abstract

This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The recent literature has been extracted for new evidence from randomized controlled trials, open treatment studies and reported expert opinion, both in original articles and reviews, and evaluates indications and safety issues based on published data. After data extraction from published full length publications and critically weighing the evidence and potential impact of the data, the review has been drafted and circulated within the National MS Societies and the European MS Platform to reach consensus within a very large group of European experts, combining evidence-based criteria and expert opinion where evidence is still incomplete. The review also outlines a few areas of controversy and delineates the need for future research.

Original languageEnglish
Pages (from-to)1449-1463
Number of pages15
JournalJournal of Neurology
Volume255
Issue number10
DOIs
StatePublished - Oct 2008

Keywords

  • Glatirameracetate
  • Immunotherapy
  • Interferon β
  • Monoclonal antibodies
  • Multiple sclerosis
  • Randomized trials
  • Treatment escalation

Fingerprint

Dive into the research topics of 'Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations'. Together they form a unique fingerprint.

Cite this